← All trials
NCT03883802
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 12, 2019
- Primary completion
- Mar 14, 2022
- Completion date
- Mar 14, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- WntResearch ABLead sponsor
- Catalan Institute of OncologyCollaborator
- Catalan Institute of OncologyOverall official - principal investigator
- Unilabs A/SCollaborator
- SMS-Oncology BVCollaborator
- SAGA diagnostics ABCollaborator
- BioVica ABCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.